Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
70.20
+1.70 (2.48%)
At close: Feb 17, 2026, 4:00 PM EST
68.00
-2.20 (-3.13%)
After-hours: Feb 17, 2026, 7:21 PM EST
Arcellx Employees
Arcellx had 163 employees as of December 31, 2024. The number of employees increased by 33 or 25.38% compared to the previous year.
Employees
163
Change (1Y)
33
Growth (1Y)
25.38%
Revenue / Employee
$220,233
Profits / Employee
-$1,336,828
Market Cap
4.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 163 | 33 | 25.38% |
| Dec 31, 2023 | 130 | 32 | 32.65% |
| Dec 31, 2022 | 98 | 20 | 25.64% |
| Dec 31, 2021 | 78 | 47 | 151.61% |
| Dec 31, 2019 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Corcept Therapeutics | 500 |
| Amicus Therapeutics | 499 |
| Crinetics Pharmaceuticals | 437 |
| TG Therapeutics | 374 |
| CG Oncology | 113 |
| Erasca | 103 |
ACLX News
- 13 days ago - Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder - Business Wire
- 27 days ago - Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings - Business Wire
- 2 months ago - Arcellx: Funded Into 2028 With Strong Clinical Data - Seeking Alpha
- 2 months ago - Cancer Study Buoys These Small Biotechs - Barrons
- 2 months ago - Why Is Arcellx Stock Surging Today? - Benzinga
- 2 months ago - Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript - Seeking Alpha
- 2 months ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire
- 3 months ago - Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition - Business Wire